Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians

Objective. Tranexamic Acid (TXA) is currently the only drug with prospective clinical evidence supporting its use in bleeding trauma patients. We sought to better understand the barriers preventing its use and elicit suggestions to further its use in trauma patients in the state of Maryland. Methods...

Full description

Bibliographic Details
Main Author: Abdulaziz Alburaih
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Emergency Medicine International
Online Access:http://dx.doi.org/10.1155/2017/4235785
id doaj-702f5092c55545dda6934c54a844ff7a
record_format Article
spelling doaj-702f5092c55545dda6934c54a844ff7a2020-11-25T00:37:39ZengHindawi LimitedEmergency Medicine International2090-28402090-28592017-01-01201710.1155/2017/42357854235785Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency PhysiciansAbdulaziz Alburaih0Department of Emergency Medicine, University of Maryland Shore Regional Health, Easton, MD, USAObjective. Tranexamic Acid (TXA) is currently the only drug with prospective clinical evidence supporting its use in bleeding trauma patients. We sought to better understand the barriers preventing its use and elicit suggestions to further its use in trauma patients in the state of Maryland. Methods. This is a cross-sectional study. Results. The overall response rate was 38%. Half of all participants reported being familiar with the CRASH-2 trial and MATTERs study. Half reported being aware of TXA as part of their institution’s massive transfusion protocol. The majority of participants felt that TXA would have a significant positive impact on the survival of trauma patients. A majority also felt that the use of TXA would increase if its administration was the responsibility of both trauma surgeons and emergency physicians. Conclusion. Only half of responders reported being aware of TXA as being part of their institution’s massive transfusion protocol. Lack of awareness of the clinical data supporting its use is a major barrier. However, most trauma providers and emergency physicians do have a favorable view of TXA and support its incorporation into massive transfusion protocols. We believe that more studies of this kind on both state and national level are needed.http://dx.doi.org/10.1155/2017/4235785
collection DOAJ
language English
format Article
sources DOAJ
author Abdulaziz Alburaih
spellingShingle Abdulaziz Alburaih
Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
Emergency Medicine International
author_facet Abdulaziz Alburaih
author_sort Abdulaziz Alburaih
title Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
title_short Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
title_full Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
title_fullStr Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
title_full_unstemmed Tranexamic Acid (TXA) in Trauma Patients: Barriers to Use among Trauma Surgeons and Emergency Physicians
title_sort tranexamic acid (txa) in trauma patients: barriers to use among trauma surgeons and emergency physicians
publisher Hindawi Limited
series Emergency Medicine International
issn 2090-2840
2090-2859
publishDate 2017-01-01
description Objective. Tranexamic Acid (TXA) is currently the only drug with prospective clinical evidence supporting its use in bleeding trauma patients. We sought to better understand the barriers preventing its use and elicit suggestions to further its use in trauma patients in the state of Maryland. Methods. This is a cross-sectional study. Results. The overall response rate was 38%. Half of all participants reported being familiar with the CRASH-2 trial and MATTERs study. Half reported being aware of TXA as part of their institution’s massive transfusion protocol. The majority of participants felt that TXA would have a significant positive impact on the survival of trauma patients. A majority also felt that the use of TXA would increase if its administration was the responsibility of both trauma surgeons and emergency physicians. Conclusion. Only half of responders reported being aware of TXA as being part of their institution’s massive transfusion protocol. Lack of awareness of the clinical data supporting its use is a major barrier. However, most trauma providers and emergency physicians do have a favorable view of TXA and support its incorporation into massive transfusion protocols. We believe that more studies of this kind on both state and national level are needed.
url http://dx.doi.org/10.1155/2017/4235785
work_keys_str_mv AT abdulazizalburaih tranexamicacidtxaintraumapatientsbarrierstouseamongtraumasurgeonsandemergencyphysicians
_version_ 1725300129578090496